{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:06:02Z","timestamp":1792785962320,"version":"4.5.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Scientific and Medical Affairs Consulting, LLC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ceftobiprole was non-inferior to comparators for the treatment of Staphylococcus aureus bloodstream infection (bacteraemia) (SAB), acute bacterial skin and skin structure infection (ABSSSI), and community-acquired bacterial pneumonia (CABP), leading to regulatory approval for these indications. Whether dosing should be modified for patients with obesity is unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This post hoc analysis evaluated the relationship of obesity and clinical outcomes in patients treated with ceftobiprole for SAB, ABSSSI or CABP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Efficacy and safety outcomes were assessed based on BMI from three registrational clinical trials that evaluated ceftobiprole against comparators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, 1641 patients were included from the three Phase 3 clinical trials (802 ceftobiprole; 839 comparators). When stratifying by BMI, ceftobiprole had similar outcomes to the overall ceftobiprole population (80.4%) including patients with obesity (BMI\u200a=\u200a30\u201340\u2005kg\/m2) (81.7%). Severe obesity (BMI\u200a\u2265\u200a40\u2005kg\/m2) was associated with decreased clinical cure rates overall (68.2%) compared with the overall ceftobiprole population, and this was especially noted in the clinically evaluable patient population with CABP receiving ceftobiprole (66.7% in severe obesity versus 86.6% overall). This was also seen in the comparator group (33.3% in severe obesity versus 87.4% overall). However, the number of patients with severe obesity was low in the CABP trial. The safety profile was similar between treatment groups in all studies and not influenced by BMI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This analysis further supports the efficacy and safety of ceftobiprole at current recommended doses in obese patients with SAB, ABSSSI or CABP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf096","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T16:20:01Z","timestamp":1742314801000},"page":"1526-1534","source":"Crossref","is-referenced-by-count":1,"title":["Impact of obesity on clinical outcomes in patients treated with ceftobiprole: results from Phase 3 clinical trials"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7745-9010","authenticated-orcid":false,"given":"Thomas L","family":"Holland","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Duke University School of Medicine , Durham, NC ,","place":["USA"]},{"name":"Duke Clinical Research Institute, Duke University School of Medicine , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew F","family":"Shorr","sequence":"additional","affiliation":[{"name":"Section of Pulmonary, Critical Care, and Respiratory Services, MedStar Washington Hospital Center , Washington, District of Columbia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Scott","family":"Overcash","sequence":"additional","affiliation":[{"name":"Velocity Clinical Research , San Diego, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Engelhardt","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd , Allschwil ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Jones","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd , Allschwil ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ionescu","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd , Allschwil ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karine","family":"Litherland","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd , Allschwil ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Saulay","sequence":"additional","affiliation":[{"name":"Basilea Pharmaceutica International Ltd , Allschwil ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Vance G","family":"Fowler","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Duke University School of Medicine , Durham, NC ,","place":["USA"]},{"name":"Duke Clinical Research Institute, Duke University School of Medicine , Durham, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"key":"2025060219524738900_dkaf096-B1","article-title":"Obesity and overweight","author":"WHO","year":"2024"},{"key":"2025060219524738900_dkaf096-B2","doi-asserted-by":"publisher","first-page":"e0171923","DOI":"10.1128\/aac.01719-23","article-title":"Updated antimicrobial dosing recommendations for obese patients","volume":"68","author":"Castro-Balado","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2025060219524738900_dkaf096-B3","first-page":"379","article-title":"Vancomycin nephrotoxicity: myths and facts","volume":"69","author":"Gupta","year":"2011","journal-title":"Neth J Med"},{"key":"2025060219524738900_dkaf096-B4","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/phar.1298","article-title":"Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States","volume":"33","author":"Bookstaver","year":"2013","journal-title":"Pharmacotherapy"},{"key":"2025060219524738900_dkaf096-B5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1146\/annurev-pharmtox-010814-124354","article-title":"Drug disposition in obesity: toward evidence-based dosing","volume":"55","author":"Knibbe","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2025060219524738900_dkaf096-B6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1080\/17425255.2018.1440287","article-title":"Obesity and drug pharmacology: a review of the influence of obesity on pharmacokinetic and pharmacodynamic parameters","volume":"14","author":"Smit","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2025060219524738900_dkaf096-B7","article-title":"Zevtera\u2122 (ceftobiprole medocaril injection) for intravenous use","author":"Basilea Pharmaceutica International Ltd","year":"2024"},{"key":"2025060219524738900_dkaf096-B8","author":"AVIR Pharma Inc"},{"key":"2025060219524738900_dkaf096-B9","doi-asserted-by":"crossref","article-title":"Pharmacokinetics and pharmacodynamics of ceftobiprole in adults who are severely obese","author":"Schmitt-Hoffmann","DOI":"10.26226\/morressier.56d6be79d462b80296c97c40"},{"key":"2025060219524738900_dkaf096-B10","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1056\/NEJMoa2300220","article-title":"Ceftobiprole for treatment of complicated Staphylococcus aureus bacteremia","volume":"389","author":"Holland","year":"2023","journal-title":"N Engl J Med"},{"key":"2025060219524738900_dkaf096-B11","doi-asserted-by":"publisher","first-page":"e1507","DOI":"10.1093\/cid\/ciaa974","article-title":"Ceftobiprole compared with vancomycin plus aztreonam in the treatment of acute bacterial skin and skin structure infections: results of a phase 3, randomized, double-blind trial (TARGET)","volume":"73","author":"Overcash","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025060219524738900_dkaf096-B12","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ijantimicag.2011.11.005","article-title":"A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation","volume":"39","author":"Nicholson","year":"2012","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 2","key":"2025060219524738900_dkaf096-B13","doi-asserted-by":"publisher","first-page":"51S","DOI":"10.1002\/j.1550-8528.1998.tb00690.x","article-title":". Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults\u2013the evidence report","volume":"6","author":"National Institutes of Health","year":"1998","journal-title":"Obes Res"},{"key":"2025060219524738900_dkaf096-B14","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"key":"2025060219524738900_dkaf096-B15","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/cpt.2181","article-title":"Antimicrobial dosing in specific populations and novel clinical methodologies: obesity","volume":"109","author":"Pai","year":"2021","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/6\/1526\/62798518\/dkaf096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/6\/1526\/62798518\/dkaf096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T19:52:55Z","timestamp":1748893975000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/6\/1526\/8099166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":15,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3,28]]},"published-print":{"date-parts":[[2025,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf096","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,3,28]]}}}